FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q46573008> ?p ?o ?g. }

• Q46573008 description "2013 nî lūn-bûn" @default.
• Q46573008 description "2013 թվականի նոյեմբերի 7-ին հրատարակված գիտական հոդված" @default.
• Q46573008 description "2013年の論文" @default.
• Q46573008 description "2013年学术文章" @default.
• Q46573008 description "2013年学术文章" @default.
• Q46573008 description "2013年学术文章" @default.
• Q46573008 description "2013年学术文章" @default.
• Q46573008 description "2013年学术文章" @default.
• Q46573008 description "2013年学术文章" @default.
• Q46573008 description "2013年學術文章" @default.
• Q46573008 description "2013年學術文章" @default.
• Q46573008 description "2013年學術文章" @default.
• Q46573008 description "2013年學術文章" @default.
• Q46573008 description "2013年學術文章" @default.
• Q46573008 description "2013년 논문" @default.
• Q46573008 description "article científic" @default.
• Q46573008 description "article scientific" @default.
• Q46573008 description "article scientifique" @default.
• Q46573008 description "articol științific" @default.
• Q46573008 description "articolo scientifico" @default.
• Q46573008 description "artigo científico" @default.
• Q46573008 description "artigo científico" @default.
• Q46573008 description "artigo científico" @default.
• Q46573008 description "artikel ilmiah" @default.
• Q46573008 description "artikull shkencor" @default.
• Q46573008 description "artikulong pang-agham" @default.
• Q46573008 description "artykuł naukowy" @default.
• Q46573008 description "artículo científico publicado en 2013" @default.
• Q46573008 description "artículu científicu" @default.
• Q46573008 description "bilimsel makale" @default.
• Q46573008 description "bài báo khoa học" @default.
• Q46573008 description "naučni članak" @default.
• Q46573008 description "scienca artikolo" @default.
• Q46573008 description "scientific article published on 7 November 2013" @default.
• Q46573008 description "scientific article published on 7 November 2013" @default.
• Q46573008 description "scientific article published on 7 November 2013" @default.
• Q46573008 description "teaduslik artikkel" @default.
• Q46573008 description "tieteellinen artikkeli" @default.
• Q46573008 description "tudományos cikk" @default.
• Q46573008 description "vedecký článok" @default.
• Q46573008 description "vetenskaplig artikel" @default.
• Q46573008 description "videnskabelig artikel" @default.
• Q46573008 description "vitenskapelig artikkel" @default.
• Q46573008 description "vitskapeleg artikkel" @default.
• Q46573008 description "vědecký článek" @default.
• Q46573008 description "wetenschappelijk artikel" @default.
• Q46573008 description "wissenschaftlicher Artikel" @default.
• Q46573008 description "επιστημονικό άρθρο" @default.
• Q46573008 description "мақолаи илмӣ" @default.
• Q46573008 description "наукова стаття, опублікована в листопаді 2013" @default.
• Q46573008 description "научна статия" @default.
• Q46573008 description "научная статья" @default.
• Q46573008 description "научни чланак" @default.
• Q46573008 description "научни чланак" @default.
• Q46573008 description "מאמר מדעי" @default.
• Q46573008 description "مقالة علمية نشرت في 7 نوفمبر 2013" @default.
• Q46573008 description "৭ নভেম্বর ২০১৩-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
• Q46573008 description "บทความทางวิทยาศาสตร์" @default.
• Q46573008 description "სამეცნიერო სტატია" @default.
• Q46573008 name "Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma." @default.
• Q46573008 name "Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma." @default.
• Q46573008 type Item @default.
• Q46573008 label "Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma." @default.
• Q46573008 label "Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma." @default.
• Q46573008 prefLabel "Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma." @default.
• Q46573008 prefLabel "Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma." @default.
• Q46573008 P1433 Q46573008-3C4F46A9-9859-46D3-934E-FFAA39D74E03 @default.
• Q46573008 P1476 Q46573008-55E0EF10-CEC9-4B7E-975F-291E01916AD3 @default.
• Q46573008 P2093 Q46573008-0EB8898D-5616-4E14-83CC-DFBA319E6675 @default.
• Q46573008 P2093 Q46573008-1D31DAE8-9BD0-441B-B8F1-13AAC89E4F49 @default.
• Q46573008 P2093 Q46573008-6D182ABF-5C0B-4817-A4F4-F4AF41D9049C @default.
• Q46573008 P2093 Q46573008-6F867C26-BC01-4F10-BC67-DCBBBCA79471 @default.
• Q46573008 P2093 Q46573008-8FF23628-7CB0-4D35-9274-A5998AC660A1 @default.
• Q46573008 P2093 Q46573008-A58D3ED6-46AE-488A-985E-95C5F2319EE9 @default.
• Q46573008 P2093 Q46573008-C8787758-F720-4A00-9553-8F180F4EE258 @default.
• Q46573008 P275 Q46573008-ef3ac2da-f8c5-4449-b8c2-8cc4fa54b0a6 @default.
• Q46573008 P2888 Q46573008-36A5BCD4-9222-4E12-81A0-673E1099664E @default.
• Q46573008 P304 Q46573008-55B1B629-8651-4E22-9B4A-87DB85FD3C69 @default.
• Q46573008 P31 Q46573008-85246011-3B05-413B-A7D4-86BF0AE91309 @default.
• Q46573008 P356 Q46573008-4A52D27A-3417-4AB9-A8D6-51D5BB8E417A @default.
• Q46573008 P433 Q46573008-83491B3E-BECC-42C7-9753-283C78EB1E5C @default.
• Q46573008 P478 Q46573008-2DAEC078-4B09-4AB2-AC69-4A7ECCB32C18 @default.
• Q46573008 P50 Q46573008-04BF6D71-A4EE-4448-AA2E-529E6B61745E @default.
• Q46573008 P577 Q46573008-50CD6DD8-C7A8-45C7-9948-EE8BAB6C1532 @default.
• Q46573008 P5875 Q46573008-169D06DA-A433-4468-AAB7-180230CE8851 @default.
• Q46573008 P6179 Q46573008-B852AE96-92D9-497C-953B-90317D51EEC7 @default.
• Q46573008 P6216 Q46573008-2e10cfd5-3029-4c6b-8598-0a7ac9c46660 @default.
• Q46573008 P921 Q46573008-485F7335-E77C-43EA-A73B-087E8FF71FD5 @default.
• Q46573008 P921 Q46573008-B7467774-1948-4E43-A465-A77C006EE0D2 @default.
• Q46573008 P921 Q46573008-EBD38436-F623-414A-B760-A267C850312D @default.
• Q46573008 P932 Q46573008-99E49A80-C4B1-4A9A-8F30-4A057824399C @default.
• Q46573008 P356 2051-1426-1-S1-P84 @default.
• Q46573008 P1433 Q27725163 @default.
• Q46573008 P1476 "Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma" @default.
• Q46573008 P2093 "Ai Li" @default.
• Q46573008 P2093 "Ari VanderWalde" @default.
• Q46573008 P2093 "David Minor" @default.
• Q46573008 P2093 "Howard Kaufman" @default.
• Q46573008 P2093 "Mohammed Milhem" @default.
• Q46573008 P2093 "Omid Hamid" @default.

• next